

Publicaties 2021 MS Centrum Amsterdam

1. Alexander S, Peryer G, Gray E, Barkhof F, Chataway J. Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review. *Mult Scler*. 2021 Oct;27(11):1643-1656. doi: 10.1177/1352458520946005. Epub 2020 Aug 4. PMID: 32749928; PMCID: PMC8474332.
2. Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintoré M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D; CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. *Mult Scler Relat Disord*. 2021 Apr;49:102717. doi: 10.1016/j.msard.2020.102717. Epub 2020 Dec 24. PMID: 33476880.
3. Beaino W, Janssen B, Vugts DJ, de Vries HE, Windhorst AD. Towards PET imaging of the dynamic phenotypes of microglia. *Clin Exp Immunol*. 2021 Dec;206(3):282-300. doi: 10.1111/cei.13649. Epub 2021 Aug 16. PMID: 34331705 Free PMC article. Review.
4. Bergaglio T, Luchicchi A, Schenk GJ. Engine Failure in Axo-Myelinic Signaling: A Potential Key Player in the Pathogenesis of Multiple Sclerosis. *Front Cell Neurosci*. 2021 Feb 10;15:610295. doi: 10.3389/fncel.2021.610295. PMID: 33642995; PMCID: PMC7902503.
5. Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, vanDam KPJ, Stalman EW, Vogelzang EH, Cristianawati O, Keijzer S, Vidarsson G, Voskuyl AE, Wieske L, Eftimov F, van Vollenhoven R, Kuijpers TW, van Ham SM, Tas SW, Killestein J, Boers M, Nurmohamed MT, Rispens T, Wolbink G. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies. *Lancet Rheumatol*. 2021 Nov;3(11):e778-e788. doi: 10.1016/S2665-9913(21)00222-8. Epub 2021 Aug 6. PMID: 34396154; PMCID: PMC8346242.
6. Boekel L, Kummer LY, van Dam KPJ, Hooijberg F, van Kempen Z, Vogelzang EH, Wieske L, Eftimov F, van Vollenhoven R, Kuijpers TW, van Ham SM, Tas SW, Killestein J, Boers M, Nurmohamed MT, Rispens T, Wolbink G. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. *Lancet Rheumatol*. 2021 Jun 18. doi: 10.1016/S2665-9913(21)00181-8.
7. Boekel L, Hooijberg F, van Kempen ZLE, Vogelzang EH, Tas SW, Killestein J, Nurmohamed MT, Boers M, Kuijpers TW, van Ham SM, Eftimov F, Wieske L, Rispens T, Wolbink GJ. Perspective of patients with autoimmune diseases on COVID-19 vaccination. *Lancet Rheumatol*. 2021 Feb 22. doi: 10.1016/S2665-9913(21)00037-0.
8. Bosma AR, Murley C, Aspling J, Hillert J, G Schaafsma F, R Anema J, Boot CRL, Alexanderson K, Machado A, Friberg E. Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation. *Mult Scler*. 2021 Oct 6:13524585211048759. doi: 10.1177/13524585211048759. Epub ahead of print. PMID: 34612098.
9. Bouman PM, Strijbis VI, Jonkman LE, Hulst HE, Geurts JJ, Steenwijk MD. Artificial double inversion recovery images for (juxta)cortical lesion visualization in multiple sclerosis. *Mult Scler*. 2021 Jul 14:13524585211029860. doi: 10.1177/13524585211029860. Epub ahead of print. PMID: 34259591.

10. Bridel C, Leurs CE, van Lierop ZYG, van Kempen ZLE, Dekker I, Twaalfhoven HAM, Moraal B, Barkhof F, Uitdehaag BMJ, Killestein J, Teunissen CE. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. *Neurology*. 2021 Nov 9;97(19):e1898-e1905. doi: 10.1212/WNL.0000000000012752. Epub 2021 Sep 9. PMID: 34504023.
11. Bridel C, Verberk IMW, Heijst JJA, Killestein J, Teunissen CE. Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients. *Mult Scler Relat Disord*. 2021 Jan;47:102666. doi: 10.1016/j.msard.2020.102666. Epub 2020 Dec 1. PMID: 33291033.
12. Burggraaff J, Liu Y, Prieto JC, Simoes J, de Sitter A, Ruggieri S, Brouwer I, Lissenberg-Witte BI, Rocca MA, Valsasina P, Ropele S, Gasperini C, Gallo A, Pareto D, Sastre-Garriga J, Enzinger C, Filippi M, De Stefano N, Ciccarelli O, Hulst HE, Wattjes MP, Barkhof F, Uitdehaag BMJ, Vrenken H, Guttman CRG; MAGNIMS Study Group. Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. *Neuroimage Clin*. 2021;29:102549. doi: 10.1016/j.nicl.2020.102549. Epub 2020 Dec 25. PMID: 33401136; PMCID: PMC7787946.
13. Castelnovo G, Gerlach O, Freedman MS, Bergmann A, Sinay V, Castillo-Triviño T, Kong G, Koster T, Williams H, Gafson AR, Killestein J. Safety, Patient- Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study. *CNS Drugs*. 2021 Sep;35(9):1009-1022. doi: 10.1007/s40263-021-00840-x. Epub 2021 Jul 28. PMID: 34322853; PMCID: PMC8408054.
14. Chalkou K, Steyerberg E, Bossuyt P, Subramaniam S, Benkert P, Kuhle J, Disanto G, Kappos L, Zecca C, Egger M, Salanti G. Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis. *Diagn Progn Res*. 2021 Oct 27;5(1):17. doi: 10.1186/s41512-021-00106-6. PMID: 34706759; PMCID: PMC8549310.
15. Chard DT, Alahmadi AAS, Audoin B, Charalambous T, Enzinger C, Hulst HE, Rocca MA, Rovira À, Sastre-Garriga J, Schoonheim MM, Tijms B, Tur C, Gandini Wheeler- Kingshott CAM, Wink AM, Ciccarelli O, Barkhof F; MAGNIMS Study Group. Mind the gap: from neurons to networks to outcomes in multiple sclerosis. *Nat Rev Neurol*. 2021 Mar;17(3):173-184. doi: 10.1038/s41582-020-00439-8. Epub 2021 Jan 12. PMID: 33437067.
16. Charvet B, Pierquin J, Brunel J, Gorter R, Quétard C, Horvat B, Amor S, Portoukalian J, Perron H. Human Endogenous Retrovirus Type W Envelope from Multiple Sclerosis Demyelinating Lesions Shows Unique Solubility and Antigenic Characteristics. *Viol Sin*. 2021 Oct;36(5):1006-1026. doi: 10.1007/s12250-021-00372-0. Epub 2021 Mar 26. PMID: 33770381; PMCID: PMC8558138.
17. Cloosterman S, Wijnands I, Huygens S, Wester V, Lam KH, Strijbis E, den Teuling B, Versteegh M. The Potential Impact of Digital Biomarkers in Multiple Sclerosis in The Netherlands: An Early Health Technology Assessment of MS Sherpa. *Brain Sci*. 2021 Sep 30;11(10):1305. doi: 10.3390/brainsci11101305. PMID: 34679370; PMCID: PMC8534078.
18. Coerver EME, Wessels MHJ, van Lierop ZYG, van Kempen ZLE, Killestein J, Strijbis EMM. Natalizumab discontinuation in a Dutch real-world cohort. *Mult Scler Relat Disord*. 2021 Jul;52:102974. doi: 10.1016/j.msard.2021.102974. Epub 2021 Apr 24. PMID: 33990055.

19. Colato E, Stutters J, Tur C, Narayanan S, Arnold DL, Gandini Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O, Chard DT, Eshaghi A. Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. *J Neurol Neurosurg Psychiatry*. 2021 Sep;92(9):995-1006. doi: 10.1136/jnnp-2020-325610. Epub 2021 Apr 20. PMID:33879535; PMCID: PMC8372398.
20. Collorone S, Kanber B, Hashem L, Cawley N, Prados F, Davagnanam I, Barkhof F, Ciccarelli O, Toosy A. Visual Function and Brief Cognitive Assessment for Multiple Sclerosis in Optic Neuritis Clinically Isolated Syndrome Patients. *J Neuro ophthalmol*. 2021 Sep 23. doi: 10.1097/WNO.0000000000001280. Epub ahead of print. PMID: 34561401.
21. Collorone S, Prados F, Kanber B, Cawley NM, Tur C, Grussu F, Solanky BS, Yiannakas M, Davagnanam I, Wheeler-Kingshott CAMG, Barkhof F, Ciccarelli O, Toosy AT. Brain microstructural and metabolic alterations detected in vivo at onset of the first demyelinating event. *Brain*. 2021 Jun 22;144(5):1409-1421. doi: 10.1093/brain/awab043. PMID: 33903905; PMCID: PMC8219367.
22. Cortese R, Tur C, Prados F, Schneider T, Kanber B, Moccia M, Wheeler- Kingshott CAG, Thompson AJ, Barkhof F, Ciccarelli O. Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. *Mult Scler*. 2021 Jan;27(1):28-38. doi: 10.1177/1352458519900971. Epub 2020 Jan 21. PMID: 31961242.
23. de Sitter A, Burggraaff J, Bartel F, Palotai M, Liu Y, Simoes J, Ruggieri S, Schregel K, Ropele S, Rocca MA, Gasperini C, Gallo A, Schoonheim MM, Amann M, Yiannakas M, Pareto D, Wattjes MP, Sastre-Garriga J, Kappos L, Filippi M, Enzinger C, Frederiksen J, Uitdehaag B, Guttman CRG, Barkhof F, Vrenken H. Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. *Neuroimage Clin*. 2021;30:102659. doi: 10.1016/j.nicl.2021.102659. Epub 2021 Apr 6. PMID: 33882422; PMCID: PMC8082260.
24. Dekker I, Schoonheim MM, Venkatraghavan V, Eijlers AJC, Brouwer I, Bron EE, Klein S, Wattjes MP, Wink AM, Geurts JGG, Uitdehaag BMJ, Oxtoby NP, Alexander DC, Vrenken H, Killestein J, Barkhof F, Wottschel V. The sequence of structural, functional and cognitive changes in multiple sclerosis. *Neuroimage Clin*. 2021;29:102550. doi: 10.1016/j.nicl.2020.102550. Epub 2020 Dec 24. PMID: 33418173; PMCID: PMC7804841.
25. Derada Troletti C, Enzmann G, Chiurchiù V, Kamermans A, Tietz SM, Norris PC, Jahromi NH, Leuti A, van der Pol SMA, Schouten M, Serhan CN, de Vries HE, Engelhardt B, Kooij G. Pro-resolving lipid mediator lipoxin A₄ attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome. *Cell Rep*. 2021 Jun 1;35(9):109201. doi: 10.1016/j.celrep.2021.109201. PMID: 34077725; PMCID: PMC8491454.
26. Doelman W, Marqvorsen MHS, Chiodo F, Bruijns SCM, van der Marel GA, van Kooyk Y, van Kasteren SI, Araman C. Synthesis of Asparagine Derivatives Harboring a Lewis X Type DC-SIGN Ligand and Evaluation of their Impact on Immunomodulation in Multiple Sclerosis. *Chemistry*. 2021 Feb 5;27(8):2742-2752. doi: 10.1002/chem.202004076. Epub 2020 Dec 28. PMID: 33090600; PMCID: PMC7898482.
27. Drop BRH, Zemel D, Wokke BHA, van Oosten BW, Dik S, Martins Jarnalo CO, Westerweel PE, de Beukelaar JWK. Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases. *Mult Scler Relat Disord*. 2021 Jan;47:102614. doi: 10.1016/j.msard.2020.102614. Epub 2020 Nov 16. PMID: 33249378.

28. Duan Y, Zhuo Z, Li H, Tian DC, Li Y, Yang L, Gao C, Zhang T, Zhang X, Shi FD, Barkhof F, Liu Y. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. *J Neurol Neurosurg Psychiatry*. 2021 Jul;92(7):709-716. doi: 10.1136/jnnp-2020-324826. Epub 2021 Mar 9. PMID: 33687975; PMCID: PMC8223649.
29. Elliott C, Momayyezsihkal P, Arnold DL, Liu D, Ke J, Zhu L, Zhu B, George IC, Bradley DP, Fisher E, Cahir-McFarland E, Stys PK, Geurts JGG, Franchimont N, Gafson A, Belachew S. Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise. *Brain Commun*. 2021 Aug 10;3(3):fcab176. doi: 10.1093/braincomms/fcab176. PMID: 34557664; PMCID: PMC8453433.
30. Eshaghi A, Young AL, Wijeratne PA, Prados F, Arnold DL, Narayanan S, Guttmann CRG, Barkhof F, Alexander DC, Thompson AJ, Chard D, Ciccarelli O. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nat Commun*. 2021 Apr 6;12(1):2078. doi: 10.1038/s41467-021-22265-2. Erratum in: *Nat Commun*. 2021 May 20;12(1):3169. PMID: 33824310; PMCID:PMC8024377.
31. Eshaghi A, Young AL, Wijeratne PA, Prados F, Arnold DL, Narayanan S, Guttmann CRG, Barkhof F, Alexander DC, Thompson AJ, Chard D, Ciccarelli O. Author Correction: Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nat Commun*. 2021 May 20;12(1):3169. doi: 10.1038/s41467-021-23538-6. Erratum for: *Nat Commun*. 2021 Apr 6;12(1):2078. PMID: 34016975; PMCID: PMC8137887.
32. Filippi M, Preziosa P, Barkhof F, Chard DT, De Stefano N, Fox RJ, Gasperini C, Kappos L, Montalban X, Moraal B, Reich DS, Rovira À, Toosy AT, Traboulsee A, Weinschenker BG, Zeydan B, Banwell BL, Rocca MA. Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. *JAMA Neurol*. 2021 Mar 1;78(3):351-364. doi: 10.1001/jamaneurol.2020.4689. PMID: 33315071.
33. Fransen NL, de Jong BA, Heß K, Kuhlmann T, Vincenten MCJ, Hamann J, Huitinga I, Smolders J. Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS. *Neurol Neuroimmunol Neuroinflamm*. 2021 Jan 27;8(2):e955. doi: 10.1212/NXI.0000000000000955. PMID: 33504635; PMCID: PMC7862088.
34. Fuchs TA, Schoonheim MM, Broeders TAA, Hulst HE, Weinstock-Guttman B, Jakimovski D, Silver J, Zivadinov R, Geurts JGG, Dwyer MG, Benedict RHB. Functional network dynamics and decreased conscientiousness in multiple sclerosis. *J Neurol*. 2021 Oct 29. doi: 10.1007/s00415-021-10860-8. Epub ahead of print. PMID: 34713325.
35. Geraldès R, Juryńczyk M, Dos Passos GR, Pichler A, Chung K, Hagens M, Ruggieri S, Auger C, Sastre-Garriga J, Enzinger C, Chard D, Barkhof F, Gasperini C, Rovira A, DeLuca G, Palace J; MAGNIMS study group. The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. *Mult Scler*. 2021 May;27(6):968-972. doi: 10.1177/1352458520943777. Epub 2020 Aug 6. PMID: 32757905; PMCID: PMC8114427.
36. Geys L, Parciak T, Pirmani A, McBurney R, Schmidt H, Malbaša T, Ziemssen T, Bergmann A, Rojas JI, Cristiano E, García-Merino JA, Fernández Ó, Kuhle J, Gobbi C, Delmas A, Simpson-Yap S, Nag N, Yamout B, Steinemann N, Seeldrayers P, Dubois B, van der Mei I, Stahmann A, Drulovic J, Pekmezovic T, Broła W, Tintore M, Kalkers N, Ivanov R, Zakaria M, Naseer MA, Van Hecke W, Grigoriadis N, Boziki M, Carra A, Pawlak MA, Dobson R, Hellwig K, Gallagher A, Leocani L, Dalla Costa G, de Carvalho Sousa NA, Van Wijmeersch B, Peeters LM. The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources. *Int J MS Care*. 2021 Nov-Dec;23(6):261-268. doi:10.7224/1537-2073.2021-006. Epub 2021 Dec 29. PMID: 35035297; PMCID: PMC8745233.

37. Goodkin O, Prados F, Vos SB, Pemberton H, Collorone S, Hagens MHJ, Cardoso MJ, Yousry TA, Thornton JS, Sudre CH, Barkhof F; MAGNIMS study group. FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis. *Neuroimage Clin.* 2021;29:102542. doi: 10.1016/j.nicl.2020.102542. Epub 2020 Dec 25. PMID: 33418171; PMCID: PMC7804983.
38. Granziera C, Wuerfel J, Barkhof F, Calabrese M, De Stefano N, Enzinger C, Evangelou N, Filippi M, Geurts JGG, Reich DS, Rocca MA, Ropele S, Rovira A, Sati P, Toosy AT, Vrenken H, Gandini Wheeler-Kingshott CAM, Kappos L; MAGNIMS Study Group. Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. *Brain.* 2021 Jun 22;144(5):1296-1311. doi:10.1093/brain/awab029. PMID: 33970206; PMCID: PMC8219362.
39. Graves JS, Killestein J. Reading the "T" Leaves of COVID-19 Vaccine Responses in Multiple Sclerosis. *Neurology.* 2021 Dec 8;10.1212/WNL.0000000000013166. doi: 10.1212/WNL.0000000000013166. Epub ahead of print. PMID: 34880090.
40. Gravesteijn AS, de Groot V, Hulst HH. The future for non-pharmacological treatments in MS: Looking back and moving forward. *Mult Scler* 2021 Oct;27(11):1640-1642. doi: 10.1177/13524585211005344
41. Haider L, Chung K, Birch G, Eshaghi A, Mangesius S, Prados F, Tur C, Ciccarelli O, Barkhof F, Chard D. Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up. *J Neurol Neurosurg Psychiatry.* 2021 Mar 30;jnnp-2020-325421. doi:10.1136/jnnp-2020-325421. Epub ahead of print. PMID: 33785581.
42. Haider L, Prados F, Chung K, Goodkin O, Kanber B, Sudre C, Yiannakas M, Samson RS, Mangesius S, Thompson AJ, Gandini Wheeler-Kingshott CAM, Ciccarelli O, Chard DT, Barkhof F. Cortical involvement determines impairment 30 years after a clinically isolated syndrome. *Brain.* 2021 Jun 22;144(5):1384-1395. doi: 10.1093/brain/awab033. PMID: 33880511; PMCID: PMC8219364.
43. Haller S, Haacke EM, Thurnher MM, Barkhof F. Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications. *Radiology.* 2021 Apr;299(1):3-26. doi: 10.1148/radiol.2021203071. Epub 2021 Feb 23. PMID:33620291.
44. Hartung HP, Derfuss T, Cree BA, Sormani MP, Selmaj K, Stutters J, Prados F, MacManus D, Schneble HM, Lambert E, Porchet H, Glanzman R, Warne D, Curtin F, Kornmann G, Buffet B, Kremer D, Küry P, Leppert D, Rückle T, Barkhof F. Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. *Mult Scler.* 2021 Jul 9:13524585211024997. doi: 10.1177/13524585211024997. Epub ahead of print. PMID: 34240656.
45. Høgestøl EA, Ghezzi S, Nygaard GO, Espeseth T, Sowa P, Beyer MK, Harbo HF, Westlye LT, Hulst HE, Alnæs D. Functional connectivity in multiple sclerosis modelled as connectome stability: A 5-year follow-up study. *Mult Scler.* 2021 Jul 14:13524585211030212. doi: 10.1177/13524585211030212. Epub ahead of print. PMID: 34259578.
46. Huiskamp M, Eijlers AJC, Broeders TAA, Pasteuning J, Dekker I, Uitdehaag BMJ, Barkhof F, Wink AM, Geurts JGG, Hulst HE, Schoonheim MM. Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis. *Neurology.* 2021 Aug 24;97(8):e794-e802. doi: 10.1212/WNL.0000000000012341. Epub 2021 Jun 7. PMID: 34099528; PMCID: PMC8397585.

47. Huitema MJD, Strijbis EMM, Luchicchi A, Bol JGJM, Plemel JR, Geurts JGG, Schenk GJ. Myelin Quantification in White Matter Pathology of Progressive Multiple Sclerosis Post-Mortem Brain Samples: A New Approach for Quantifying Remyelination. *Int J Mol Sci*. 2021 Nov 23;22(23):12634. doi: 10.3390/ijms222312634. PMID: 34884445; PMCID: PMC8657470.
48. Jandric D, Doshi A, Scott R, Paling D, Rog D, Chataway J, Schoonheim MM, Parker G, Muhlert N. A Systematic Review of Resting-State Functional MRI Connectivity Changes and Cognitive Impairment in Multiple Sclerosis. *Brain Connect*. 2021 Oct 6. doi: 10.1089/brain.2021.0104. Epub ahead of print. PMID: 34382408.
49. Kaddatz H, Joost S, Nedelcu J, Chrzanowski U, Schmitz C, Gingele S, Gudi V, Stangel M, Zhan J, Santrau E, Greiner T, Frenz J, Müller-Hilke B, Müller M, Amor S, van der Valk P, Kipp M. Cuprizone-induced demyelination triggers a CD8-pronounced T cell recruitment. *Glia*. 2021 Apr;69(4):925-942. doi: 10.1002/glia.23937. Epub 2020 Nov 27. PMID: 33245604.
50. Kalkers NF, Galan I, Kerbrat A, Tacchino A, Kamm CP, O'Connell K, McGuigan C, Edan G, Montalban X, Uitdehaag BM, Mokkink LB. Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries. *Mult Scler*. 2021 Jan;27(1):90-96. doi:
51. Kiljan S, Preziosa P, Jonkman LE, van de Berg WD, Twisk J, Pouwels PJ, Schenk GJ, Rocca MA, Filippi M, Geurts JJ, Steenwijk MD. Cortical axonal loss is associated with both gray matter demyelination and white matter tract pathology in progressive multiple sclerosis: Evidence from a combined MRI-histopathology study. *Mult Scler*. 2021 Mar;27(3):380-390. doi: 10.1177/1352458520918978. Epub 2020 May 11. PMID: 32390507; PMCID: PMC7897796.
52. Killestein J, Liguori M. Loss of Neurologic Reserve in Progressive Multiple sclerosis: A Paradigm Shift? *Neurol Clin Pract*. 2021 Aug;11(4):271-272. doi: 10.1212/CPJ.0000000000001106. PMID: 34484925; PMCID: PMC8382419.
53. Killestein J, Schoonheim MM, Voskuhl RR. B-Cell Depletion and COVID-19 Severity in Multiple Sclerosis: Remaining Challenges. *Neurology*. 2021 Nov 9;97(19):885-886. doi: 10.1212/WNL.00000000000012754. Epub 2021 Oct 5. PMID: 34610986.
54. Koch M, Mostert J, Repovic P, Bowen JD, Strijbis E, Uitdehaag B, Cutter G. Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. *Mult Scler*. 2021 Dec 30:13524585211063623. doi: 10.1177/13524585211063623. Epub ahead of print. PMID: 34965774.
55. Koch MW, Mostert J, Repovic P, Bowen JD, Strijbis E, Uitdehaag B, Cutter G. MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis. *Mult Scler*. 2021 Jul 26:13524585211031801. doi: 10.1177/13524585211031801. Epub ahead of print. PMID: 34304609.
56. Koch MW, Mostert J, Repovic P, Bowen JD, Strijbis E, Uitdehaag B, Cutter G. Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. *J Neurol*. 2021 Aug 15. doi: 10.1007/s00415-021-10750-z. Epub ahead of print. PMID: 34392376.
57. Koch MW, Mostert J, Repovic P, Bowen JD, Uitdehaag B, Cutter G. Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis? *Eur J Neurol*. 2021 Jun;28(6):2115-2120. doi: 10.1111/ene.14732. Epub 2021 Jan 24. PMID: 33448539.

58. Koch MW, Mostert J, Repovic P, Bowen JD, Uitdehaag B, Cutter G. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. *Neurology*. 2021 Jan 5;96(1):e111-e120. doi: 10.1212/WNL.0000000000011123. Epub 2020 Oct 26. PMID: 33106389.
59. Koch MW, Mostert J, Repovic P, Bowen JD, Wolinsky JS, Lublin FD, Strijbis E, Cutter G. Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis. *Eur J Neurol*. 2021 Dec 20. doi: 10.1111/ene.15220. Epub ahead of print. PMID: 34927308.
60. Koch MW, Mostert J, Zhang Y, Wolinsky JS, Lublin FD, Strijbis E, Cutter G. Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. *Neurology*. 2021 Sep 28;97(13):e1334-e1342. doi: 10.1212/WNL.0000000000012603. Epub 2021 Aug 10. PMID: 34376508; PMCID: PMC8589289.
61. Koch MW, Mostert JP, Uitdehaag B, Cutter G. A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. *Mult Scler*. 2021 Oct;27(12):1864-1874. doi: 10.1177/1352458520987539. Epub 2021 Jan 19. PMID: 33464149; PMCID: PMC8521359.
62. Koch MW, Mostert JP, Wolinsky JS, Lublin FD, Uitdehaag B, Cutter GR. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. *Neurology*. 2021 Oct 19;97(16):e1560-e1570. doi: 10.1212/WNL.0000000000012690. Epub 2021 Aug 25. PMID: 34433679.
63. Kwilas AJ, Green Fulgham SM, Duran-Malle JC, Schrama AEW, Mitten EH, Todd LS, Patel HP, Larson TA, Clements MA, Harris KM, Litwiler ST, Harvey LO Jr, Maier SF, Chavez RA, Rice KC, Van Dam AM, Watkins LR. Toll-like receptor 2 and 4 antagonism for the treatment of experimental autoimmune encephalomyelitis (EAE)-related pain. *Brain Behav Immun*. 2021 Mar;93:80-95. doi: 10.1016/j.bbi.2020.12.016. Epub 2021 Jan 7. PMID: 33358978; PMCID: PMC8475740.
64. Kwilas AJ, Todd LS, Duran-Malle JC, Schrama AEW, Mitten EH, Larson TA, Clements MA, Harris KM, Litwiler ST, Wang X, Van Dam AM, Maier SF, Rice KC, Watkins LR, Barrientos RM. Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non- opioid TLR2/TLR4 antagonist (+)-naltrexone. *Behav Brain Res*. 2021 Jan 1;396:112896. doi: 10.1016/j.bbr.2020.112896. Epub 2020 Sep 6. PMID: 32905811; PMCID: PMC7572683.
65. Lam KH, Meijer KA, Loonstra FC, Coerver E, Twose J, Redeman E, Moraal B, Barkhof F, de Groot V, Uitdehaag B, Killestein J. Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis. *Mult Scler*. 2021 Aug;27(9):1421-1431. doi: 10.1177/1352458520968797. Epub 2020 Nov 5. PMID: 33150823; PMCID: PMC8358561.
66. Lam KH, van Oirschot P, den Teuling B, Hulst HE, de Jong BA, Uitdehaag B, de Groot V, Killestein J. Reliability, construct and concurrent validity of a smartphone-based cognition test in multiple sclerosis. *Mult Scler*. 2021 May 26;13524585211018103. doi: 10.1177/13524585211018103. Epub ahead of print. PMID: 34037472.
67. Littooi E, Doodeman S, Holla J, Ouwerkerk M, Post L, Satink T, Ter Steeg AM, Vloothuis J, Dekker J, de Groot V. Setting meaningful goals in rehabilitation: A qualitative study on the experiences of clients and clinicians in working with a practical tool. *Clin Rehabil*. 2021 Nov 3:2692155211046463. doi: 10.1177/02692155211046463. Epub ahead of print. PMID: 34730459.

68. Luchicchi A, Hart B, Frigerio I, van Dam AM, Perna L, Offerhaus HL, Stys PK, Schenk GJ, Geurts JGG. Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter. *Ann Neurol*. 2021 Apr;89(4):711-725. doi:10.1002/ana.26014. Epub 2021 Jan 27. PMID: 33410190; PMCID: PMC8048993.
69. Luchicchi A, Preziosa P, 't Hart B. Editorial: "Inside-Out" vs "Outside-In" Paradigms in Multiple Sclerosis Etiopathogenesis. *Front Cell Neurosci*. 2021 Mar 1;15:666529. doi: 10.3389/fncel.2021.666529. PMID: 33732113; PMCID: PMC7957074.
70. Lukas C, Bellenberg B, Prados F, Valsasina P, Parmar K, Brouwer I, Pareto D, Rovira À, Sastre-Garriga J, Gandini Wheeler-Kingshott CAM, Kappos L, Rocca MA, Filippi M, Yiannakas M, Barkhof F, Vrenken H. Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. *Front Neurol*. 2021 Aug 4;12:693333. doi: 10.3389/fneur.2021.693333. PMID: 34421797; PMCID: PMC8371197.
71. Meier UC, Cipian RC, Karimi A, Ramasamy R, Middeldorp JM. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. *Front Immunol*. 2021 Nov 1;12:757302. doi: 10.3389/fimmu.2021.757302. PMID: 34790199; PMCID: PMC8592026.
72. Meneguette NS, Almeida KMFR, Figueiredo MTJO, de Araújo E Araújo ACR, Alvarenga MP, Vasconcelos CCF, Nascimento ACB, Colombini GNUI, Petzold A, Alvarenga RMP. Optic neuritis in Asian type opticospinal multiple sclerosis (OSMS-ON) in a non-Asian population: A functional-structural paradox. *Mult Scler Relat Disord*. 2021 Nov;56:103260. doi: 10.1016/j.msard.2021.103260. Epub 2021 Sep 9. PMID: 34562767.
73. Michels RE, Peters ML, Schiffers KM, Bouma PA, Hengstman GI, van Munster CE, Zeinstra E, Voer G, Krol M. A Delphi panel on treatment of high disease activity relapsing remitting multiple sclerosis in the Netherlands. *J Comp Eff Res*. 2021 Feb;10(2):93-100. doi: 10.2217/cer-2020-0140. Epub 2020 Dec 4. PMID: 33275036.
74. Moccia M, Haider L, Eshaghi A, van de Pavert SHP, Brescia Morra V, Patel A, Wheeler-Kingshott CAM, Barkhof F, Ciccarelli O. B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2021 Nov 10;9(1):e1108. doi: 10.1212/NXI.0000000000001108. PMID: 34759021; PMCID: PMC8587731.
75. Momtazmanesh S, Shobeiri P, Saghadzadeh A, Teunissen CE, Burman J, Szalardy L, Klivenyi P, Bartos A, Fernandes A, Rezaei N. Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. *Rev Neurosci*. 2021 Feb 17;32(6):573-595. doi: 10.1515/revneuro-2020-0145. PMID: 33594840.
76. Nauta IM, Bertens D, van Dam M, Huiskamp M, Driessen S, Geurts J, Uitdehaag B, Fasotti L, Hulst HE, de Jong BA, Klein M. Performance validity in outpatients with multiple sclerosis and cognitive complaints. *Mult Scler*. 2021 Jul 2;13524585211025780. doi: 10.1177/13524585211025780. Epub ahead of print. PMID:34212754.
77. Nauta IM, Kulik SD, Breedts LC, Eijlers AJ, Strijbis EM, Bertens D, Tewarie P, Hillebrand A, Stam CJ, Uitdehaag BM, Geurts JJ, Douw L, de Jong BA, Schoonheim MM. Functional brain network organization measured with magnetoencephalography predicts cognitive decline in multiple sclerosis. *Mult Scler*. 2021 Oct;27(11):1727-1737. doi: 10.1177/1352458520977160. Epub 2020 Dec 9. PMID: 33295249; PMCID: PMC8474326.

78. Nij Bijvank JA, Sánchez Aliaga E, Balk LJ, Coric D, Davagnanam I, Tan HS, Uitdehaag BMJ, van Rijn LJ, Petzold A. A model for interrogating the clinico-radiological paradox in multiple sclerosis: Internuclear ophthalmoplegia. *Eur J Neurol.* 2021 May;28(5):1617-1626. doi: 10.1111/ene.14723. Epub 2021 Feb 8. PMID:33426786; PMCID: PMC8248033.
79. Nij Bijvank JA, Strijbis EMM, Nauta IM, Kulik SD, Balk LJ, Stam CJ, Hillebrand A, Geurts JJG, Uitdehaag BMJ, van Rijn LJ, Petzold A, Schoonheim MM. Impaired saccadic eye movements in multiple sclerosis are related to altered functional connectivity of the oculomotor brain network. *Neuroimage Clin* 2021;32:102848. doi: 10.1016/j.nicl.2021.102848. Epub 2021 Oct 4. PMID: 34624635; PMCID: PMC8503580.
80. Nutma E, Gebro E, Marzin MC, van der Valk P, Matthews PM, Owen DR, Amor S. Activated microglia do not increase 18 kDa translocator protein (TSPO) expression in the multiple sclerosis brain. *Glia.* 2021 Oct;69(10):2447-2458. doi: 10.1002/glia.24052. Epub 2021 Jun 19. PMID: 34145928; PMCID: PMC8453709.
81. Nutma E, Marzin MC, Cillessen SA, Amor S. Autophagy in white matter disorders of the CNS: mechanisms and therapeutic opportunities. *J Pathol.* 2021 Feb;253(2):133-147. doi: 10.1002/path.5576. Epub 2020 Dec 4. PMID: 33135781; PMCID: PMC7839724.
82. Oosterveer DM, van den Berg C, Volker G, Wouda NC, Terluin B, Hoitsma E. Determining the minimal important change of the 6-minute walking test in Multiple Sclerosis patients using a predictive modelling anchor-based method. *Mult Scler Relat Disord.* 2021 Nov 30;57:103438. doi: 10.1016/j.msard.2021.103438. Epub ahead of print. PMID: 34871859.
83. Ottiger B, Van Wegen E, Keller K, Nef T, Nyffeler T, Kwakkel G, Vanbellinghen T. Getting into a "Flow" state: a systematic review of flow experience in neurological diseases. *J Neuroeng Rehabil.* 2021 Apr 20;18(1):65. doi: 10.1186/s12984-021-00864-w. PMID: 33879182; PMCID: PMC8059246.
84. Paul F, Calabresi PA, Barkhof F, Green AJ, Kardon R, Sastre-Garriga J, Schippling S, Vermersch P, Saidha S, Gerendas BS, Schmidt-Erfurth U, Agoropoulou C, Zhang Y, Seifer G, Petzold A. Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. *Ann Clin Transl Neurol.* 2021 Dec;8(12):2235-2251. doi: 10.1002/acn3.51473. Epub 2021 Nov 18. PMID: 34792863; PMCID: PMC8670323.
85. Peeters LM, Parciak T, Kalra D, Moreau Y, Kasilingam E, van Galen P, Thalheim C, Uitdehaag B, Vermersch P, Hellings N, Stinissen P, Van Wijmeersch B, Ardeshirdavani A, Pirmani A, De Brouwer E, Bauer CR, Krefting D, Ribbe S, Middleton R, Stahmann A, Comi G. Multiple Sclerosis Data Alliance - A global multi-stakeholder collaboration to scale-up real world data research. *Mult Scler Relat Disord.* 2021 Jan;47:102634. doi: 10.1016/j.msard.2020.102634. Epub 2020 Nov 21. PMID: 33278741.
86. Perez-Muñoz ME, Sugden S, Harmsen HJM, 't Hart BA, Laman JD, Walter J. Nutritional and ecological perspectives of the interrelationships between diet and the gut microbiome in multiple sclerosis: Insights from marmosets. *iScience.* 2021 Jun 10;24(7):102709. doi: 10.1016/j.isci.2021.102709. PMID: 34296070; PMCID: PMC8282968.

87. Petzold A, Albrecht P, Balcer L, Bekkers E, Brandt AU, Calabresi PA, Deborah OG, Graves JS, Green A, Keane PA, Nij Bijvank JA, Sander JW, Paul F, Saidha S, Villoslada P, Wagner SK, Yeh EA; IMSVISUAL, ERN-EYE Consortium. Artificial intelligence extension of the OSCAR-IB criteria. *Ann Clin Transl Neurol*. 2021 Jul;8(7):1528-1542. doi: 10.1002/acn3.51320. Epub 2021 May 19. PMID: 34008926; PMCID: PMC8283174.
88. Petzold A, Chua SYL, Khawaja AP, Keane PA, Khaw PT, Reisman C, Dhillon B, Strouthidis NG, Foster PJ, Patel PJ; UK Biobank Eye and Vision Consortium. Retinal asymmetry in multiple sclerosis. *Brain*. 2021 Feb 12;144(1):224-235. doi: 10.1093/brain/awaa361. PMID: 33253371; PMCID: PMC7880665.
89. Picon C, Jayaraman A, James R, Beck C, Gallego P, Witte ME, van Horssen J, Mazarakis ND, Reynolds R. Neuron-specific activation of necroptosis signaling in multiple sclerosis cortical grey matter. *Acta Neuropathol*. 2021 Apr;141(4):585-604. doi: 10.1007/s00401-021-02274-7. Epub 2021 Feb 10. PMID: 33569629; PMCID: PMC7952371.
90. Preziosa P, Bouman PM, Kiljan S, Steenwijk MD, Meani A, Pouwels PJ, Rocca MA, Filippi M, Geurts JGG, Jonkman LE. Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2021 Jul;92(7):790-792. doi: 10.1136/jnnp-2020-324391. Epub 2021 Jan 12. PMID: 33436500.
91. Preziosa P, Schoonheim MM. Ongoing Axonal Injury in Chronic Active Lesions in Multiple Sclerosis: In Vivo Quantification Using Serum Neurofilament. *Neurology*. 2021 Aug 10;97(6):257-258. doi: 10.1212/WNL.0000000000012331. Epub 2021 Jun 4. PMID: 34088879.
92. Prouskas SE, Chiaravalloti ND, Kant N, Ball KK, de Groot V, Uitdehaag BM, Geurts JJ, Kooij EA, Hulst HE. Feasibility of cognitive rehabilitation in patients with advanced multiple sclerosis: A pilot study. *Mult Scler J Exp Transl Clin*. 2021 Dec 10;7(4):20552173211064473. doi: 10.1177/20552173211064473. PMID: 34917392; PMCID: PMC8669124.
93. Puentes F, Benkert P, Amor S, Kuhle J, Giovannoni G. Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. *BMJ Neurol Open*. 2021 Nov 11;3(2):e000192. doi: 10.1136/bmjno-2021-000192. PMID: 34786556; PMCID: PMC8587694.
94. Ramaglia V, Dubey M, Malpede MA, Petersen N, de Vries SI, Ahmed SM, Lee DSW, Schenk GJ, Gold SM, Huitinga I, Gommerman JL, Geurts JGG, Kole MHP. Complement-associated loss of CA2 inhibitory synapses in the demyelinated hippocampus impairs memory. *Acta Neuropathol*. 2021 Oct;142(4):643-667. doi: 10.1007/s00401-021-02338-8. Epub 2021 Jun 25. PMID: 34170374; PMCID: PMC8423657.
95. Rijnsburger M, Djuric N, Mulder IA, de Vries HE. Adipokines as Immune Cell Modulators in Multiple Sclerosis. *Int J Mol Sci*. 2021 Oct 7;22(19):10845. doi: 10.3390/ijms221910845. PMID: 34639186; PMCID: PMC8509121.
96. Rocca MA, Valsasina P, Meani A, Gobbi C, Zecca C, Rovira A, Sastre-Garriga J, Kearney H, Ciccarelli O, Matthews L, Palace J, Gallo A, Biseco A, Lukas C, Bellenberg B, Barkhof F, Vrenken H, Preziosa P, Filippi M; MAGNIMS Study Group. Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. *Neurology*. 2021 Mar 16;96(11):e1561-e1573. doi: 10.1212/WNL.0000000000011494. Epub 2021 Jan 13. Erratum in: *Neurology*. 2021 Aug 10;97(6):300. PMID: 33441452.

97. Rosenkranz SC, Shaposhnykov AA, Träger S, Engler JB, Witte ME, Roth V, Vieira V, Paauw N, Bauer S, Schwencke-Westphal C, Schubert C, Bal LC, Schattling B, Pless O, van Horssen J, Freichel M, Friese MA. Enhancing mitochondrial activity in neurons protects against neurodegeneration in a mouse model of multiple sclerosis. *Elife*. 2021 Feb 10;10:e61798. doi: 10.7554/eLife.61798. PMID: 33565962; PMCID: PMC7993994.
98. Scherder RJ, Prins AJ, van Dorp MJ, van Klaveren C, Cornelisz I, Killestein J, Weinstein H. Pain, cognition and disability in advanced multiple sclerosis. *Scand J Pain*. 2021 Sep 2;21(4):754-765. doi: 10.1515/sjpain-2021-0067. PMID:34469640.
99. Schoonheim MM, Douw L, Broeders TA, Eijlers AJ, Meijer KA, Geurts JJ. The cerebellum and its network: Disrupted static and dynamic functional connectivity patterns and cognitive impairment in multiple sclerosis. *Mult Scler*. 2021 Nov;27(13):2031-2039. doi: 10.1177/1352458521999274. Epub 2021 Mar 8. PMID:33683158; PMCID: PMC8564243.
100. Sestito C, Leurs CE, Steenwijk MD, Brevé JJP, Twisk JWR, Wilhelmus MMM, Drukarch B, Teunissen CE, van Dam AM, Killestein J. Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm*. 2021 Apr 27;8(4):e998. doi: 10.1212/NXI.0000000000000998. PMID: 33906937; PMCID: PMC8105890.
101. Sormani MP, Tur C, Barkhof F. Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis? *Neurology*. 2021 Jan 26;96(4):141-142. doi: 10.1212/WNL.0000000000011312. Epub 2020 Dec 2. PMID: 33268561.
102. Spaas J, Franssen WMA, Keytsman C, Blancquaert L, Vanmierlo T, Bogie J, Broux B, Hellings N, van Horssen J, Posa DK, Hoetker D, Baba SP, Derave W, Eijnde BO. Carnosine quenches the reactive carbonyl acrolein in the central nervous system and attenuates autoimmune neuroinflammation. *J Neuroinflammation*. 2021 Nov 5;18(1):255. doi: 10.1186/s12974-021-02306-9. PMID: 34740381; PMCID: PMC8571880.
103. Spaas J, van Veggel L, Schepers M, Tiane A, van Horssen J, Wilson DM 3rd, Moya PR, Piccart E, Hellings N, Eijnde BO, Derave W, Schreiber R, Vanmierlo T. Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders. *Cell Mol Life Sci*. 2021 May;78(10):4615-4637. doi: 10.1007/s00018-021-03802-0. Epub 2021 Mar 10. PMID: 33751149; PMCID: PMC8195802.
104. Strijbis EMM, Kerbrat A, Corboy JR. Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go? *JAMA Neurol*. 2021 Jul 1;78(7):787-788. doi: 10.1001/jamaneurol.2021.0764. PMID: 33871561.
105. Strik M, Chard DT, Dekker I, Meijer KA, Eijlers AJ, Pardini M, Uitdehaag BM, Kolbe SC, Geurts JJ, Schoonheim MM. Increased functional sensorimotor network efficiency relates to disability in multiple sclerosis. *Mult Scler*. 2021 Aug;27(9):1364-1373. doi: 10.1177/1352458520966292. Epub 2020 Oct 26. PMID:33104448; PMCID: PMC8358536.
106. Strik M, Cofré Lizama LE, Shanahan CJ, van der Walt A, Boonstra FMC, Glarin R, Kilpatrick TJ, Geurts JJG, Cleary JO, Schoonheim MM, Galea MP, Kolbe SC. Axonal loss in major sensorimotor tracts is associated with impaired motor performance in minimally disabled multiple sclerosis patients. *Brain Commun*. 2021 Mar 16;3(2):fcab032. doi: 10.1093/braincomms/fcab032. PMID: 34222866; PMCID: PMC8244644.

107. Strik M, Shanahan CJ, van der Walt A, Boonstra FMC, Glarin R, Galea MP, Kilpatrick TJ, Geurts JGG, Cleary JO, Schoonheim MM, Kolbe SC. Functional correlates of motor control impairments in multiple sclerosis: A 7 Tesla task functional MRI study. *Hum Brain Mapp.* 2021 Jun 1;42(8):2569-2582. doi: 10.1002/hbm.25389. Epub 2021 Mar 5. PMID: 33666314; PMCID: PMC8090767.
108. 't Hart BA, Luchicchi A, Schenk GJ, Killestein J, Geurts JGG. Multiple sclerosis and drug discovery: A work of translation. *EBioMedicine.* 2021 Jun;68:103392. doi: 10.1016/j.ebiom.2021.103392. Epub 2021 May 24. PMID: 34044219; PMCID: PMC8245896.
109. 't Hart BA, Luchicchi A, Schenk GJ, Stys PK, Geurts JGG. Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis. *Ann Clin Transl Neurol.* 2021 Aug;8(8):1709-1719. doi: 10.1002/acn3.51401. Epub 2021 Jun 22. PMID: 34156169; PMCID: PMC8351380.
110. Ten Bosch GJA, Bolk J, 't Hart BA, Laman JD. Multiple sclerosis is linked to MAPK^{ERK} overactivity in microglia. *J Mol Med (Berl).* 2021 Aug;99(8):1033-1042. doi: 10.1007/s00109-021-02080-4. Epub 2021 May 5. PMID: 33948692; PMCID: PMC8313465.
111. Teo W, Caprariello AV, Morgan ML, Luchicchi A, Schenk GJ, Joseph JT, Geurts JGG, Stys PK. Nile Red fluorescence spectroscopy reports early physicochemical changes in myelin with high sensitivity. *Proc Natl Acad Sci U S A.* 2021 Feb 23;118(8):e2016897118. doi: 10.1073/pnas.2016897118. PMID: 33593907; PMCID: PMC7923366.
112. Tijhuis FB, Broeders TAA, Santos FAN, Schoonheim MM, Killestein J, Leurs CE, van Geest Q, Steenwijk MD, Geurts JGG, Hulst HE, Douw L. Dynamic functional connectivity as a neural correlate of fatigue in multiple sclerosis. *Neuroimage Clin.* 2021;29:102556. doi: 10.1016/j.nicl.2020.102556. Epub 2021 Jan 4. PMID:33472144; PMCID: PMC7815811.
113. Toorop AA, Rispens T, Strijbis EM, van Oosten BW, de Jong BA, Uitdehaag BM, Killestein J, van Kempen ZL. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis. *Mult Scler.* 2021 Dec 21:13524585211052168. doi: 10.1177/13524585211052168. Epub ahead of print. PMID: 34931887.
114. van Dam M, Hulst HE, Schoonheim MM. Coupling structure and function in early MS: How a less diverse repertoire of brain function could lead to clinical progression. *Mult Scler.* 2021 Apr;27(4):491-493. doi: 10.1177/1352458520987798. PMID: 33719745.
115. van Dam M, Sikkes SA, Rammello E, Reinders E, Jelgerhuis JR, Geurts JJ, Uitdehaag BM, Hulst HE. Cognitive functioning in everyday life: The development of a questionnaire on instrumental activities of daily living in multiple sclerosis. *Mult Scler J Exp Transl Clin.* 2021 Aug 3;7(3):20552173211038027. doi: 10.1177/20552173211038027. PMID: 34408904; PMCID: PMC8365017.
116. van Kempen ZL, Toorop AA, Sellebjerg F, Giovannoni G, Killestein J. Extended dosing of monoclonal antibodies in multiple sclerosis. *Mult Scler.* 2021 Dec 24:13524585211065711. doi: 10.1177/13524585211065711. Epub ahead of print. PMID: 34949134.
117. van Kempen ZLE, Strijbis EMM, Al MMCT, Steenhuis M, Uitdehaag BMJ, Rispens T, Killestein J. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort. *JAMA Neurol.* 2021 Jul 1;78(7):880-882. doi: 10.1001/jamaneurol.2021.1364. PMID: 33929488; PMCID: PMC8087977.

118. van Kempen ZLE, van Rossum JA, Hoogervorst E, Strijbis E, Toorop A, Bosscha MI, Frequin S, Dam-van Loon NT, Wattjes MP, Murk JL, Killestein J, Uitdehaag BMJ. Varicella zoster-associated acute retinal necrosis and central nervous system complications in natalizumab treated MS patients. *Mult Scler Relat Disord*. 2021 May;50:102838. doi: 10.1016/j.msard.2021.102838. Epub 2021 Feb 10. PMID: 33609925.
119. van Kempen ZLE, Wieske L, Stalman EW, Kummer LYL, van Dam PJ, Volkers AG, Boekel L, Toorop AA, Strijbis EMM, Tas SW, Wolbink GJ, Löwenberg M, van Sandt C, Ten Brinke A, Versteegen NJM, Steenhuis M, Kuijpers TW, van Ham SM, Rispens T, Eftimov F, Killestein J; T2B! immunity against SARS-CoV-2 study group. Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: To wait and repopulate? *Mult Scler Relat Disord*. 2021 Nov 23;57:103416. doi: 10.1016/j.msard.2021.103416. Epub ahead of print. PMID: 34847379; PMCID: PMC8608662.
120. van Kempen ZL, Killestein J, Hartung HP. Keep your eyes on the prize: Tackling breakthrough COVID-19 in MS patients. *Mult Scler*. 2021 Dec;27(14):2123-2125. doi: 10.1177/13524585211057511. PMID: 34783282
121. van Lierop Z, Toorop AA, Coerver E, Willemse E, Strijbis E, Kalkers NF, Moraal B, Barkhof F, Teunissen CE, Killestein J, van Kempen Z. Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. *Mult Scler J Exp Transl Clin*. 2021 Jun 1;7(2):20552173211013831. doi: 10.1177/20552173211013831. PMID: 34123391; PMCID: PMC8175839.
122. van Lierop ZY, Toorop AA, van Ballegoij WJ, Olde Dubbelink TB, Strijbis EM, de Jong BA, van Oosten BW, Moraal B, Teunissen CE, Uitdehaag BM, Killestein J, Kempen ZLV. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. *Mult Scler*. 2021 Jul 9;13524585211028833. doi: 10.1177/13524585211028833. Epub ahead of print. PMID: 34240631.
123. van Olst L, Rodriguez-Mogeda C, Picon C, Kiljan S, James RE, Kamermans A, van der Pol SMA, Knoop L, Michailidou I, Drost E, Franssen M, Schenk GJ, Geurts JGG, Amor S, Mazarakis ND, van Horsen J, de Vries HE, Reynolds R, Witte ME. Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration. *Acta Neuropathol*. 2021 Jun;141(6):881-899. doi: 10.1007/s00401-021-02293-4. Epub 2021 Mar 29. PMID: 33779783; PMCID: PMC8113309.
124. van 't Hullenaar CAA, Coerver E, Kalkers NF, van Kempen Z, Koch M, Uitdehaag BMJ, Killestein J, Strijbis EMM. The use of multi-domain patient reported outcome measures for detecting clinical disease progression in multiple sclerosis. *Mult Scler Relat Disord*. 2021 Oct;55:103165. doi: 10.1016/j.msard.2021.103165. Epub 2021 Jul 29. PMID: 34404022.
125. van Wageningen TA, Antonovaite N, Paardekam E, Brevé JJP, Iannuzzi D, van Dam AM. Viscoelastic properties of white and gray matter-derived microglia differentiate upon treatment with lipopolysaccharide but not upon treatment with myelin. *J Neuroinflammation*. 2021 Mar 29;18(1):83. doi: 10.1186/s12974-021-02134-x. PMID: 33781276; PMCID: PMC8008683.
126. van Wageningen TA, Gerrits E, Palacin I, Bonson S, Huitinga I, Eggen BJL, van Dam AM. Exploring reported genes of microglia RNA-sequencing data: Uses and considerations. *Glia*. 2021 Dec;69(12):2933-2946. doi: 10.1002/glia.24078. Epub 2021 Aug 18. PMID: 34409652.

127. Veldkamp R, Goetschalckx M, Hulst HE, Nieuwboer A, Grieten K, Baert I, Leone C, Moumdjian L, Feys P. Cognitive-motor Interference in Individuals With a Neurologic Disorder: A Systematic Review of Neural Correlates. *Cogn Behav Neurol*. 2021 Jun 2;34(2):79-95. doi: 10.1097/WNN.000000000000269. PMID:34074863.
128. Verberk IMW, Koel-Simmelink M, Twaalfhoven H, Vrenken H, Korth C, Killestein J, Teunissen CE, Bridel C. Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. *Mult Scler Relat Disord*. 2021 May;50:102840. doi: 10.1016/j.msard.2021.102840. Epub 2021 Feb 10. PMID: 33626430.
129. Verberk SGS, van der Zande HJP, Baardman J, de Goede KE, Harber KJ, Keuning ED, Lambooi JM, Otto F, Zawistowska-Deniziak A, de Vries HE, de Winther MPJ, Guigas B, Van den Bossche J. Myeloid ATP Citrate Lyase Regulates Macrophage Inflammatory Responses *In Vitro* Without Altering Inflammatory Disease Outcomes. *Front Immunol*. 2021 Apr 26;12:669920. doi: 10.3389/fimmu.2021.669920. PMID: 33981315; PMCID: PMC8107722.
130. Vrenken H, Jenkinson M, Pham DL, Guttmann CRG, Pareto D, Paardekooper M, de Sitter A, Rocca MA, Wottschel V, Cardoso MJ, Barkhof F; MAGNIMS Study Group. Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence. *Neurology*. 2021 Nov 23;97(21):989-999. doi: 10.1212/WNL.0000000000012884. Epub 2021 Oct 4. PMID: 34607924; PMCID: PMC8610621.
131. Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, Fazekas F, Filippi M, Frederiksen J, Gasperini C, Hacoen Y, Kappos L, Li DKB, Mankad K, Montalban X, Newsome SD, Oh J, Palace J, Rocca MA, Sastre-Garriga J, Tintoré M, Traboulsee A, Vrenken H, Yousry T, Barkhof F, Rovira À; Magnetic Resonance Imaging in Multiple Sclerosis study group; Consortium of Multiple Sclerosis Centres; North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. *Lancet Neurol*. 2021 Aug;20(8):653-670. doi: 10.1016/S1474-4422(21)00095-8. Epub 2021 Jun 14. PMID: 34139157.
132. Wijburg MT, Warnke C, McGuigan C, Koralnik IJ, Barkhof F, Killestein J, Wattjes MP. Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. *J Neurol Neurosurg Psychiatry*. 2021 Feb;92(2):177-188. doi: 10.1136/jnnp-2020-324534. Epub 2020 Nov 23. PMID: 33229453.
133. Zhan J, Fegg FN, Kaddatz H, Rühling S, Frenz J, Denecke B, Amor S, Ponsaerts P, Hochstrasser T, Kipp M. Focal white matter lesions induce long- lasting axonal degeneration, neuroinflammation and behavioral deficits. *Neurobiol Dis*. 2021 Jul;155:105371. doi: 10.1016/j.nbd.2021.105371. Epub 2021 Apr 29. PMID: 33932559.
134. Zheng F, Li Y, Zhuo Z, Duan Y, Cao G, Tian D, Zhang X, Li K, Zhou F, Huang M, Li H, Li Y, Zeng C, Zhang N, Sun J, Yu C, Han X, Hallar S, Barkhof F, Liu Y. Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder. *Mult Scler*. 2021 Aug 11:13524585211032800. doi: 10.1177/13524585211032800. Epub ahead of print. PMID: 34379008.
135. Zhuo Z, Li Y, Duan Y, Cao G, Zheng F, Ding J, Tian D, Wang X, Wang J, Zhang X, Li K, Zhou F, Huang M, Li Y, Li H, Zeng C, Zhang N, Sun J, Yu C, Han X, Haller S, Barkhof F, Shi F, Liu Y. Subtyping relapsing-remitting multiple sclerosis using structural MRI. *J Neurol*. 2021 May;268(5):1808-1817. doi: 10.1007/s00415-020-10376-7. Epub 2021 Jan 2. PMID: 33387013.